Recently, MoMed Biotech's R&D team announced the first batch of activity and animal experiment data for the breast cancer PROTAC pipeline. The initial results obtained from the research, which was designed using MoMed Biotech's MechGen multidimensional intelligent technology platform, indicate that the PROTAC protein degrader molecule CZ-501, which targets ER degradation, performs excellently in terms of both efficacy and safety, with its activity and other indicators reaching the best level in the industry.

Momed Biotech (Hangzhou) Biotechnology Co., Ltd., a process spanning nearly five months, saw the completion of its over 1000m2 office renovation project, which commenced in December 2022. In April 2023, much anticipated by many, Chenzhu Technology officially relocated to 60 Hongfeng Road, Linping District, Hangzhou.

In August 2022, Professor Bai Chen was interviewed by ' China High-tech ' magazine. He described his experience in the field of macromolecular mechanism research of drug targets and his vision and goals for the future of the biomedical industry. The relevant report is published in the ' China High-tech ' magazine in August 2022.